Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yvo de Beer"'
Autor:
Joost Wauters, Sander Croes, Yvo de Beer, Johan Maertens, Roger J. M. Brüggemann, Isabel Spriet, Rob E. Aarnoutse, Ruth Van Daele
Publikováno v:
Journal of Antimicrobial Chemotherapy, 76, 961-966
Journal of Antimicrobial Chemotherapy, 76(4), 961-966. Oxford University Press
Journal of Antimicrobial Chemotherapy, 76, 4, pp. 961-966
Journal of Antimicrobial Chemotherapy, 76(4), 961-966. Oxford University Press
Journal of Antimicrobial Chemotherapy, 76, 4, pp. 961-966
ObjectivesLiposomal amphotericin B is widely used to treat life-threatening invasive fungal infections and has replaced conventional amphotericin B deoxycholate due to its more favourable toxicity profile. Despite the fact that liposomal amphotericin
Autor:
Ruth Van Daele, Joost Wauters, Omar Elkayal, Erwin Dreesen, Yves Debaveye, Katrien Lagrou, Yvo de Beer, Johan Maertens, Roger J Brüggemann, Isabel Spriet
Publikováno v:
Medical Mycology, 60
Medical Mycology. Informa Healthcare
Medical Mycology, 60, 10
Medical Mycology. Informa Healthcare
Medical Mycology, 60, 10
Liposomal amphotericin B (L-AmB) is a broad-spectrum antifungal drug. Little is known about its pharmacokinetics (PK) in critically ill patients. The aim of this study was to document the PK of L-AmB in this population. It was also explored if covari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21489093093e702b45167dec384585f6
http://hdl.handle.net/2066/287857
http://hdl.handle.net/2066/287857
Autor:
Roy Schoufs, Sander Croes, Leo M L Stolk, Ard van Veelen, Robin M. J. M. van Geel, Yvo de Beer, Lizza E.L. Hendriks
Publikováno v:
Biomedical Chromatography, 35(12):e5224. John Wiley & Sons Inc.
A liquid chromatography-tandem mass spectrometry method was developed and validated to quantify alectinib, crizotinib, erlotinib and gefitinib. This assay can be combined with our method for osimertinib, allowing quantification of the most used ALK-
Autor:
Roeland E Wasmann, Cornelis Smit, Roger J. M. Brüggemann, René M J Wiezer, Jill Adler-Moore, David M. Burger, Eric P H van Dongen, Yvo de Beer, Catherijne A. J. Knibbe
Publikováno v:
Clinical Infectious Diseases, 70, 2213-2215
Clinical Infectious Diseases, 70(10):ciz885, 2213-2215. Oxford University Press
Clinical Infectious Diseases, 70(10), 2213-2215. Oxford University Press
Clinical Infectious Diseases, 70, 10, pp. 2213-2215
Clinical Infectious Diseases, 70(10):ciz885, 2213-2215. Oxford University Press
Clinical Infectious Diseases, 70(10), 2213-2215. Oxford University Press
Clinical Infectious Diseases, 70, 10, pp. 2213-2215
Contains fulltext : 220654.pdf (Publisher’s version ) (Open Access) In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clea
Autor:
Sander Croes, Yvo de Beer, Robin M. J. M. van Geel, Anne-Marie C. Dingemans, Ard van Veelen, Frank de Vries, Rob ter Heine, Leo M L Stolk
Publikováno v:
Biomedical Chromatography, 34, 4, pp. e4771
Biomedical Chromatography, 34, e4771
Biomedical Chromatography, 34(4), 1. John Wiley and Sons Ltd
Biomedical Chromatography, 34(4):e4771. John Wiley & Sons Inc.
Biomedical Chromatography, 34, e4771
Biomedical Chromatography, 34(4), 1. John Wiley and Sons Ltd
Biomedical Chromatography, 34(4):e4771. John Wiley & Sons Inc.
Contains fulltext : 218134.pdf (Publisher’s version ) (Closed access) A new method for quantification of osimertinib (OSIM) in human plasma using a high-performance liquid chromatography-tandem mass spectrometry method was developed and validated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ba3860be9ffcb8a98f56076d9d06c9
https://doi.org/10.1002/bmc.4771
https://doi.org/10.1002/bmc.4771
Autor:
Mirjam G. W. Arens van der Logt, Petronella B. Ottevanger, Winette T. A. van der Graaf, Carla M.L. van Herpen, Marye J Boers-Sonderen, Ingrid M.E. Desar, Yvo de Beer, Nielka P. van Erp
Publikováno v:
Cancer Chemotherapy and Pharmacology, 74(3), 457-463. Springer Verlag
Cancer Chemotherapy and Pharmacology, 74, 457-63
Cancer Chemotherapy and Pharmacology, 74, 3, pp. 457-63
Cancer Chemotherapy and Pharmacology, 74, 457-63
Cancer Chemotherapy and Pharmacology, 74, 3, pp. 457-63
Item does not contain fulltext PURPOSE: Pegylated liposomal doxorubicin (PLD) is used to treat patients with breast and gynecological cancers. In order to optimize treatment with PLD, we assessed the prognostic and predictive factors for efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3b98b44b42fa3c47aa57fa88ab889d
https://cris.maastrichtuniversity.nl/en/publications/15e5e2b0-7f51-4c04-a215-5ed50c6b914c
https://cris.maastrichtuniversity.nl/en/publications/15e5e2b0-7f51-4c04-a215-5ed50c6b914c